

References

- Eldrup, A.B., Prhavc, M., Brooks, J., Bhat, B., Prakash, T.P., Song, Q., Bera, S., Bhat, N., Dande, P., Cook, P.D., Bennett, C.F., Carroll, S.S., Ball, R.G., Bosserman, M., Burlein, C., Colwell, L.F., Fay, J.F., Flores, O.A., Getty, K., LaFemina, R.L., Leone, J., MacCoss, M., McMasters, D.R., Tomassini, J.E., Von Langen, D., Wolanski, B., Olsen, D.B., 2004. Structure–activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. *J. Med. Chem.* 47, 5284–5297.
- Perrone, P., Luoni, G.M., Kelleher, M.R., Daverio, F., Angell, A., Mulready, S., Congiatu, C., Rajyaguru, S., Martin, J.A., Levêque, V., Le Pogam, S., Najera, I., Klumpp, K., Smith, D.B., McGuigan, C., 2007. Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. *J. Med. Chem.* 50, 1840–1849.

doi:10.1016/j.antiviral.2009.02.051

47

Use of the BelloCell System to Determine the Optimal Dose of Ribavirin to Inhibit the Expression of an HCV Replicon in 2209-23 Cells

James McSharry*, Diane Singer, Robert Kulawy, Ashley Brown, George Drusano

Ordway Research Institute, Albany, USA

Introduction: To use antiviral compounds effectively for the treatment of hepatitis C virus (HCV) infections in man, one must know the optimal dose and schedule of administration of compounds that will inhibit virus replication without leading to the emergence of resistant viruses. We used the BelloCell system to determine the optimal dose of ribavirin that will inhibit the in vitro expression of an HCV replicon in 2209-23 cells.

Methods: HCV replicon containing 2209-23 cells were obtained from Roche Pharmaceuticals Inc., Palo Alto, CA. The replicon contains a neomycin gene for its detection and quantitation by RT-PCR and a luciferase gene for its detection and quantitation using the *Renilla* Luciferase Assay. To determine a dose response of ribavirin, 10⁸ 2209-23 cells were added to each of four BelloCell systems containing DMEM supplemented with 10% fetal bovine serum. The systems were incubated at 37°C, 5% CO₂ for 7–10 days. One unit was continuously infused with medium without ribavirin, the others contained either 10, 20 or 40 µM ribavirin. Fresh ribavirin was added daily. PK/PD analysis of the concentration of ribavirin in each unit was determined daily by LC/MS/MS. Each day, 20 flakes were taken from each BelloCell unit, the cells were removed with trypsin/EDTA, counted, normalized to 5000 cells and the luciferase activity in these cells was determined using a luminometer. The HCV replicons in the remainder of the cells were quantified by kinetic RT-PCR.

Results: The EC₅₀ value for ribavirin for this replicon system is about 20 µM when determined in the standard 96 well format. A similar EC₅₀ value was found when these replicon containing cells were treated with various concentrations of ribavirin in the BelloCell system.

Conclusion: The results of this proof-of-principle study suggests that the BelloCell system can be used to determine the dose of antiviral compounds effective against HCV. With knowledge of the EC₅₀ values, the BelloCell system could be used to perform a dose fractionation assay to determine the pharmacodynamically linked variable for antiviral compounds effective against hepatitis C virus.

doi:10.1016/j.antiviral.2009.02.052

48

Silibinin (Legalon-SIL) Inhibits HCV Replication In Vitro

Isabel Najera^{1,*}, Vincent Leveque¹, Matt McCown¹, Julie Q. Hang¹, Han Ma¹, Sonal Rajyaguru¹, Amy Fung¹, Yanli Yang¹, Yang Liu¹, Simran Kular¹, Nick Cammack¹, Peter Ferenci², Klaus Klumpp¹

¹ Roche, Palo Alto, USA; ² Medical University of Vienna, Vienna, Austria

Background: Intravenous Legalon-silibinin (SIL) is a potent antiviral agent in HCV infected persons. SIL monotherapy at 20 mg/kg resulted in significant viral load reduction in prior non-responders to pegylated interferon and ribavirin therapy (VL reduction of 3.0 ± 1.0 log IU/ml after 7 days). Antiviral potency of SIL was further increased in combination with pegylated interferon and ribavirin (VL reduction of 4.8 ± 0.9 log IU/ml after 7 days). The mechanism of action of SIL remained unresolved.

Methods: We determined the inhibitory activity of SIL and structurally related analogs in a number of HCV in vitro assay systems including subgenomic replicon, GT-1a infectious virus replication (HCVcc), HCV entry (HCVpp), RNA polymerase, protease and helicase. In addition, in vitro selection of SIL resistant replicons was performed.

Results: SIL inhibited HCV replication in the genotype 1a and 1b replicon systems with similar potency and IC₅₀ values in the low micromolar range. SIL was not cytotoxic (CC₅₀ > 100 µM) or cytostatic (3H-Thy incorporation IC₅₀ > 100 µM) at these concentrations. SIL also inhibited HCV replication in the GT 1a infectious virus assay (H77-HCVcc), but did not inhibit HCV entry in either the genotype 1a or 1b cell HCVpp systems, consistent with SIL targeting HCV replication. Among the HCV replication targets, HCV protease and helicase activity were not affected by SIL, whereas RNA-dependent RNA polymerase NS5B was moderately sensitive to inhibition by SIL (IC₅₀ = 50 ± 7.6 µM). SIL interfered with NS5B–RNA interaction, whereas preformed NS5B–RNA complexes were resistant to inhibition by SIL. Characterization of SIL analogs suggested structural features important for HCV replication inhibition. Results from the in vitro selection of SIL resistant replicon variants will be available and discussed at the time of presentation.

Conclusions: HCV replication was identified as a target of SIL. The ability of SIL to inhibit HCV RNA synthesis by HCV polymerase NS5B was consistent with inhibition of HCV replicon and HCV infectious virus replication in vitro, whereas HCV entry was not affected by the presence of SIL.

doi:10.1016/j.antiviral.2009.02.053

49

Therapeutic Efficacy of the Amphipathic DNA Polymer REP 9AC in the Treatment of Duck Hepatitis B Virus Infection In Vivo

Faseeha Nordeen^{1,*}, Arend Grosse^{1,2}, Jean-Marc Juteau³, Andrew Vaillant³, Allison Jilbert^{1,2}

¹ School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia; ² Infectious Diseases Laboratories, SA Pathology, Adelaide, Australia; ³ REPLICor Inc., Laval, Canada

The amphipathic DNA polymer REP 9AC has demonstrated potent antiviral activity in vitro against DHBV during viral entry and post-entry. A large amphipathic domain related to those targeted by these compounds in type 1 virus fusion proteins is likely targeted by REP 9AC in DHBV. The therapeutic potential of REP 9AC for the treatment of HBV infection in humans was assessed using DHBV-infected Pekin ducks as a surrogate model. REP 9AC (10 mg/kg) was administered 1 day prior to, or from 4 or 14 days

post-infection, to ducks inoculated with 5×10^8 DHBV genomes. The antiviral effect of REP 9AC treatment was assessed by monitoring serum viremia by quantitative PCR and serum and liver DHB sAg by ELISA or immunohistochemistry. Short-term daily (14 days) REP 9AC treatment starting 1 day prior to infection resulted in undetectable DHBV infection in 80% of ducks 53 days after cessation of treatment. The same duration of daily REP 9AC treatment starting 4 days after DHBV infection, when 2–6% of hepatocytes are typically infected led to undetectable levels of DHBV DNA in 100% of ducks within 10 days after the initiation of REP 9AC treatment and remained undetectable in 75% of ducks for 49 days after treatment. REP 9AC treatment in fully infected ducks was started 14 days after DHBV infection. Ducks received 7 daily, followed by 7 weekly doses. This treatment resulted in rapid decreases (>3 log) in serum DHBV DNA at the end of the daily treatment in all ducks. However, only 20% of the ducks had a sustained virological response 49 days after cessation of treatment. These data show that REP 9AC treatment can control post-infection spread of DHBV in Pekin ducks and can result in sustained virologic responses after treatment is halted. Thus, REP 9AC might be a valuable monotherapy or an adjunct to nucleoside analogue therapy for HBV infection. An expanded therapeutic study with longer treatment duration and followup is in progress.

doi:10.1016/j.antiviral.2009.02.054

50

Characterization of the Mechanism of Action of PG-301029: A Novel Late Stage Inhibitor of HCV Replicon Replication

Todd Parsley*, Lu Yang, Robert Buckheit Jr.

ImQuest BioSciences, Inc., Frederick, USA

PG-301029 is a small molecule that was identified as an effective inhibitor (EC_{50} value of $2.8 \mu\text{M}$) of bovine viral diarrhoea virus (BVDV). Subsequent research suggested a novel mechanism of antiviral action that resulted in a highly significant reduction of viral RNA synthesis that was not related to inhibition of virus entry, IRES translation initiation, inhibition of the NS2/3 or NS3/4A viral proteinase activities, or the NS5B viral RNA-dependent RNA polymerase. PG-301029 was 100- to 200-fold less toxic than ribavirin to cells infected with BVDV, and facilitated a reduction in the toxicity of ribavirin in combination anti-BVDV assays. PG-301029 was also shown to be nontoxic to fresh human hepatocytes at the highest concentration tested (1.33 mM). These data suggest the possibility of using the compound as a monotherapy or in combination with ribavirin, or ribavirin plus interferon for treatment of HCV. In addition, serial passage of BVDV-infected cells in the presence of escalating doses of PG-301029 failed to select for resistant virus, suggesting a high genetic barrier for resistance and that the antiviral activity may be mediated through a cellular target. Subsequent research demonstrated that PG-301029 was efficacious in an HCV replicon system, yielding an EC_{50} value of $1.5 \mu\text{M}$ and a TC_{50} greater than 42 mM . Attempts to select PG-301029-resistant HCV replicons containing a neomycin selectable marker have demonstrated that culture of the replicon-producing cells in the presence of G418 and $7.5 \mu\text{M}$ PG-301029 resulted in replicons with three potential resistance engendering mutations—one in NS3 and two in NS5A. Based on these data, we hypothesize that PG-301029 inhibits HCV replication through a novel late stage mechanism of action. Hypothesis driven research is currently focused on the identification of the mechanism of action of PG-301029 using the HCV replicon system. Results will be presented detailing characterization of HCV replicons containing the putative resistance engendering mutations, the effect of PG-301029 on HCV RNA synthesis and stability, and gene expression examining the differential expression of host cell genes

in PG-301029 treated Huh-7 cells and Huh-7 cells transfected with HCV replicons.

doi:10.1016/j.antiviral.2009.02.055

51

Predictive Factors to Response to Interferon Therapies for Treatment-naïve Patients Infected with Hepatitis C Virus in Islamabad and Vicinity Areas: A Study from Pakistan

Abida Raza*, Hafsa Aziz, Javed Irfan

Nuclear Medicine Oncology and Radiotherapy Institute, Islamabad, Pakistan

Viral load determinations can give an idea of disease severity. The initial viral load before any treatment is needed to check the response of any interferon therapy. Hepatitis C is a silent, systemic disease that has many extrahepatic manifestations in addition to hepatic inflammation and fibrosis, some of which may result in a poor health-related quality of life. Fatigue perhaps the most frequent and disabling extrahepatic symptom of hepatitis C virus (HCV) reported in almost one-half of all chronically infected individuals. This large study (4324 patients) was conducted at Nuclear Medicine Oncology and Radiotherapy Institute on the HCV patients referred from major hospitals of Islamabad and its vicinity during the year 2006–2007. Based on their personal history data, a questionnaire was filled by all the patients visiting the hospital stating their demographic data, treatment information, biochemical tests results (ALT, bilirubin and ALK), symptoms/complaints, any family history of hepatitis, any past history of drug abuse, dialysis, blood transfusion, surgery, multipricks, dental surgery, barber and stomach problem. Interestingly almost 82% (3546) patients reported as they have the fatigue, general body ache, and leg pains. Significant number of patients 75% (3244/4324) belong to families where any of their family member was suffering from HCV. 118 patients were found to have their counterpart HCV positive which may be the case of sexually transmitted disease but it was not clear who caught the first. Naïve viral load was quantified on Corbett Research Real Time PCR system using aj Roboscreen kit. It was found on average 8×10^6 IU/ml HCV incidence is increasing in Pakistan and it is very important to have baseline data for effective treatment. This will be the first study from Pakistan stating the prevalence of treatment-naïve patient viral load.

doi:10.1016/j.antiviral.2009.02.056

52

Design, Molecular Modelling Studies of Specific Targeted Candidate Inhibitors of HCV NS5B RNA Polymerase

P. Selvam^{1,*}, M. Chandramohan², J. Pranitha³, N. Saravanan Prabhu³, Muthuvels Suresh kumar³

¹ Amrita School of Pharmacy, AIMS campus, Kochi 26, India; ² Bharat Ratna Kamarajar Jaundice, Liver Hospital and Research Centre, Madurai 01, India; ³ Centre for Bioinformatics, Pondicherry University, Puducherry 14, India

Hepatitis C virus (HCV) a member of the *Flavivirus* genus, is a negative strand RNA virus that is estimated to have infected 170 million people globally. Ribavirin and interferon combined chemotherapy is now available to treat HCV viral infection. Due to high rate of viral drug resistance, we need new targeted therapy to combat HCV. Structure-based drug design methods utilize knowledge of three-dimensional structure of an enzyme to develop some novel inhibitors of HCV. NS5B protein encoded RNA depen-